Your browser is no longer supported. Please, upgrade your browser.
Settings
ACST Acasti Pharma Inc. daily Stock Chart
ACST [NASD]
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own9.30% Shs Outstand90.21M Perf Week13.04%
Market Cap35.18M Forward P/E- EPS next Y-0.35 Insider Trans0.00% Shs Float81.84M Perf Month1.33%
Income- PEG- EPS next Q-0.16 Inst Own6.05% Short Float0.73% Perf Quarter-82.67%
Sales- P/S- EPS this Y30.30% Inst Trans- Short Ratio0.17 Perf Half Y-81.43%
Book/sh-0.30 P/B- EPS next Y34.00% ROA- Target Price2.52 Perf Year-58.95%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.25 - 3.08 Perf YTD-84.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-87.34% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low56.00% ATR0.04
Employees28 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.85 Volatility9.34% 15.25%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.25 Prev Close0.37
ShortableYes LT Debt/Eq- EarningsMay 15 BMO Payout- Avg Volume3.45M Price0.39
Recom2.00 SMA2016.08% SMA50-17.66% SMA200-74.63% Volume849,998 Change5.09%
Jan-13-20Downgrade B. Riley FBR Buy → Neutral
Aug-29-19Initiated B. Riley FBR Buy $7.75
Jul-18-19Initiated Oppenheimer Outperform $7
Jun-26-19Initiated H.C. Wainwright Buy $6
Apr-01-20 08:30AM  Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June GlobeNewswire -13.04%
Mar-11-20 08:00AM  Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico GlobeNewswire
Mar-06-20 06:50AM  Amarin Stock Looks Like a Heart-Healthy Buy on the Dip InvestorPlace -5.45%
Feb-28-20 05:00PM  Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements GlobeNewswire
02:48PM  Look Anywhere but Acasti Pharma Stock for Opportunity InvestorPlace
10:07AM  Confounding Decline Creates an Opportunity in Amarin Stock InvestorPlace
Feb-14-20 11:41AM  Risks Remain, but Amarin Stock Is a Buy at Todays Prices InvestorPlace
08:00AM  Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020 GlobeNewswire
Feb-13-20 09:00AM  Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call GlobeNewswire
Feb-11-20 11:27AM  3 Beaten-Down Biotech Stocks With +50% Upside Potential TipRanks
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 07:00AM  Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre GlobeNewswire -24.60%
Jan-17-20 11:07AM  Does Acasti Stock Have a Future? InvestorPlace
06:30AM  Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace
Jan-14-20 09:46AM  AstraZeneca to End Phase III Study on Fish Oil Heart Drug Zacks +23.68%
07:55AM  The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
Jan-13-20 04:22PM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily -65.14%
02:31PM  Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint MarketWatch
01:38PM  Neptune Provides Updates on Non-Core Investments CNW Group
11:07AM  Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short Barrons.com
09:40AM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
06:00AM  Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre GlobeNewswire
Jan-10-20 10:59AM  All Bets Are Off for Amarin Stock InvestorPlace
Jan-09-20 08:56AM  3 Healthcare Stocks With Big Catalysts in January TipRanks
Dec-24-19 09:51AM  Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides Benzinga
08:13AM  Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI Benzinga
07:24AM  The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 08:31PM  Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre GlobeNewswire -24.04%
Dec-22-19 04:43PM  Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. (ACST) Insider Monkey
Dec-20-19 04:41AM  Amarin Stock is at Sky-High Levels Already Assumes All the Good News InvestorPlace +12.11%
Nov-26-19 07:55AM  Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia GlobeNewswire
Nov-25-19 08:30AM  Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc. Newsfile
Nov-21-19 08:23AM  Amarin's Shares Down on Underperform Rating by Oppenheimer Zacks
Nov-18-19 08:38AM  Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPres Novel Mechanism of Action in Diabetes GlobeNewswire +5.39%
Nov-13-19 07:55AM  Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020 GlobeNewswire
Nov-07-19 08:30AM  Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal GlobeNewswire -5.91%
Nov-06-19 09:00AM  Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call GlobeNewswire
Nov-04-19 09:04AM  Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre® GlobeNewswire +8.81%
Oct-01-19 09:00AM  Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-30-19 08:35AM  Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 GlobeNewswire
Sep-27-19 06:05AM  Do Insiders Own Lots Of Shares In Acasti Pharma Inc. (CVE:ACST)? Simply Wall St.
Sep-09-19 08:30AM  Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity GlobeNewswire
Sep-04-19 09:00AM  Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th GlobeNewswire +10.56%
Aug-28-19 04:05PM  Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM GlobeNewswire
Aug-14-19 08:00AM  Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020 GlobeNewswire +6.22%
Aug-09-19 08:00AM  Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference GlobeNewswire -8.73%
Aug-07-19 08:00AM  Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call GlobeNewswire
Jul-25-19 03:42PM  Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital GlobeNewswire -10.26%
Jul-05-19 08:35AM  Bausch Gains 38.9% YTD on Product Launches & Debt Reduction Zacks
Jun-26-19 11:08AM  Acasti Pharma Trades Higher Despite 'Material Uncertainty' Benzinga +14.29%
11:00AM  Acasti Pharma, Inc. to Host Earnings Call ACCESSWIRE
08:05AM  Acasti Pharma Provides Fiscal 2019 Year-End Business Update GlobeNewswire
Jun-24-19 09:00AM  Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPres Omega-3 Phospholipid Composition GlobeNewswire
Jun-19-19 08:00AM  Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call GlobeNewswire +9.19%
Jun-04-19 09:15AM  Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia GlobeNewswire
May-23-19 05:00PM  Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer GlobeNewswire
May-21-19 07:30AM  Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference GlobeNewswire
May-15-19 07:55AM  Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel GlobeNewswire
May-10-19 07:30AM  Acasti Settles Claims with Former Chief Executive Officer GlobeNewswire
Apr-24-19 08:00AM  Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City GlobeNewswire
Apr-15-19 09:15AM  Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia GlobeNewswire
Apr-01-19 09:20AM  Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal GlobeNewswire
Mar-26-19 08:30AM  Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd GlobeNewswire
Mar-13-19 08:30AM  Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th GlobeNewswire
Feb-21-19 09:15AM  Acasti Pharma Recognized in TSX Venture Exchanges 2019 Venture 50 GlobeNewswire
Feb-14-19 02:57PM  Acasti: Fiscal 3Q Earnings Snapshot Associated Press +5.02%
08:05AM  Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 GlobeNewswire
Feb-08-19 08:00AM  Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call GlobeNewswire
Jan-09-19 11:58AM  4 Healthcare Stocks Looking To Set January Highs ACCESSWIRE +14.13%
08:00AM  Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office GlobeNewswire
Dec-31-18 08:00AM  Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan GlobeNewswire +13.18%
Dec-28-18 09:55AM  Generic Industry on Path to Recovery: 3 Hot Picks for 2019 Zacks +6.52%
Dec-20-18 08:00AM  Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia GlobeNewswire +8.46%
Nov-27-18 07:00AM  Acasti Pharma to Present at the 11th Annual LD Micro Main Event ACCESSWIRE -9.13%
Nov-14-18 08:53AM  Acasti: Fiscal 2Q Earnings Snapshot Associated Press -13.97%
08:00AM  Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019 GlobeNewswire
Nov-07-18 08:00AM  Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call GlobeNewswire
Oct-23-18 09:00AM  Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option GlobeNewswire +7.00%
Oct-11-18 07:30AM  Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares GlobeNewswire +5.26%
Oct-10-18 08:05AM  Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review ACCESSWIRE -8.06%
Oct-04-18 09:35AM  Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares GlobeNewswire +19.67%
07:59AM  The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga
Oct-03-18 04:23PM  Acasti Pharma Announces Public Equity Offering GlobeNewswire -12.86%
04:23PM  Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares GlobeNewswire
Oct-02-18 09:10AM  The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares Benzinga -10.83%
Oct-01-18 05:00PM  Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures GlobeNewswire +21.71%
Sep-28-18 08:17AM  Todays Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma ACCESSWIRE +30.30%
Sep-24-18 08:00AM  Acasti Pharma Appoints Jean-François Boily as Vice President of Finance GlobeNewswire +41.89%
Sep-18-18 08:52AM  Acasti Pharma Provides Clinical and Market Update GlobeNewswire
Aug-29-18 04:05PM  Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM GlobeNewswire
Aug-14-18 01:00PM  Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019 GlobeNewswire
08:39AM  Acasti: 2Q Earnings Snapshot Associated Press
Jul-31-18 05:09PM  Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan GlobeNewswire +6.67%
Jul-24-18 09:15AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office GlobeNewswire
Jul-02-18 05:00PM  Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures GlobeNewswire
Jun-28-18 08:26AM  Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut Benzinga
Jun-27-18 05:00PM  Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018 GlobeNewswire
Jun-11-18 08:07PM  Acasti Pharma Reports on Positive Feedback Following Todays Presentation at the XVIII International Symposium on Atherosclerosis GlobeNewswire
Jun-06-18 07:00AM  Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis GlobeNewswire
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.